Back to Search
Start Over
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada.
- Source :
-
CJC open [CJC Open] 2020 Dec 16; Vol. 3 (6), pp. 814-821. Date of Electronic Publication: 2020 Dec 16 (Print Publication: 2021). - Publication Year :
- 2020
-
Abstract
- Background: The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary syndromes. Recently, Effient (prasugrel [Eli Lilly Canada Inc, Toronto, Canada]) was discontinued by its distributor in Canada.<br />Methods: Five members of the Canadian Cardiovascular Society antiplatelet therapy 2018 guidelines committee undertook an independent, evidence-based review to outline patients for whom prasugrel should be the optimal P2Y12 agent and discuss alternative strategies to consider without prasugrel.<br />Results: Several clinical scenarios where prasugrel should be indicated are identified and discussed. Considerations to be undertaken for alternative therapies are summarized, including a review of national and international guidelines for de-escalation of P2Y12 receptor antagonists.<br />Conclusions: The discontinuation of prasugrel poses a challenge for clinicians. Clinicians must consider key factors in determining the best alternate therapy.<br /> (© 2021 The Authors.)
Details
- Language :
- English
- ISSN :
- 2589-790X
- Volume :
- 3
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- CJC open
- Publication Type :
- Academic Journal
- Accession number :
- 34169260
- Full Text :
- https://doi.org/10.1016/j.cjco.2020.11.021